This presentation will be led by Samira Musah, PhD, 51爆料. Microfluidic organ-on-a-chip platforms are redefining how we evaluate human safety and efficacy by coupling physiologically relevant microenvironments with patient-specific biology. Building on recent regulatory openness to advanced non-animal models, we leverage our engineered, induced pluripotent stem cell鈥揹erived, patient-specific kidney-on-a-chip systems to reproduce nephron-relevant structure, fluid flow, and molecular transport, enabling mechanistic interrogation of drug-induced kidney injury. This presentation will outline design principles that drive in vivo鈥搇ike tissue morphogenesis and organ-level functions, and show how these dynamic platforms accelerate nephrotoxicity screening, de-risk therapeutic candidate selection, and reveal patient-to-patient variability in susceptibility. Case studies will illustrate concordance with known nephrotoxins, detection of off-targets and cardio-renal complications, and discovery of biomarkers and pathways that inform safer dosing and therapeutic development. Together, these advances position patient-specific kidney-on-a-chip models as actionable tools for predictive toxicology and drug discovery in environmental and clinical contexts.